Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government
Veterans Benefits and Health Care About VA Find a VA Location

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Assessing 1-year sodium-glucose co-transporter-2 inhibitor tolerance in older adults.

Schafer SM, Zeithamel MC, Waterbury NV, Lund BC. Assessing 1-year sodium-glucose co-transporter-2 inhibitor tolerance in older adults. Age and ageing. 2024 Oct 1; 53(10).

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


Abstract:

BACKGROUND: Evidence concerning tolerability of sodium-glucose co-transporter-2 (SGLT2) inhibitors in older adults is limited due to under-representation in clinical trials. Our study aimed to determine the extent to which SGLT2 inhibitor intolerance increases with age and explore additional factors associated with intolerance. METHODS: This retrospective observational study included patients in the Veterans Health Administration who initiated an SGLT2 inhibitor between 1 January 2013 and 31 December 2021. One-year discontinuation served as a proxy for intolerance. Relative risk (RR) for 1-year discontinuation was contrasted across age groups using log-binomial regression to adjust for confounding. RESULTS: Of 232 495 patients who initiated an SGLT2 inhibitor, 60 582 (26.1%) discontinued within one year. A difference was observed across age groups, < 65, 65-74, 75-84 and? = 85 years, where 25.8%, 25.3%, 28.5% and 34.9% of patients discontinued, respectively (P? < .001). After adjustment for confounding factors, patients 75-84 and? = 85 years were at 8% (RR? = 1.08; 95% CI: 1.05, 1.10) and 21% increased risk (RR? = 1.21; 95% CI: 1.15, 1.26) for discontinuation, respectively, relative to patients < 65 years. Additional risk factors were identified: female (RR? = 1.41; 95% CI: 1.37, 1.45), estimated glomerular filtration rate stage 4 (RR? = 1.49; 95% CI: 1.39, 1.60), underweight (RR? = 1.15; 95% CI: 1.03, 1.29), urinary tract infection history (RR? = 1.25; 95% CI: 1.21, 1.30) and yeast infection history (RR? = 1.39; 95% CI: 1.27, 1.51). CONCLUSION: No clinically meaningful differences in SGLT2 inhibitor intolerance were observed in patients up to 84 years. Our findings support having closer follow-up when initiating in patients 85 years and older.




Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.